Core Insights - Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026, focusing on its AI-driven oncology drug development [1] - The company’s RADR® platform has facilitated the development of LP-184 / STAR-001, a novel therapeutic candidate for CNS cancers, including recurrent glioblastoma and pediatric brain tumors [1] - STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation, highlighting its potential in treating rare conditions [1] Company Overview - Lantern Pharma is a clinical-stage biopharmaceutical company utilizing artificial intelligence and machine learning to enhance oncology drug discovery and development [1] - The RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug responses, and design more effective clinical trials [1] - The company’s pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations [1] Presentation Highlights - CEO Panna Sharma will discuss the application of RADR® in discovering novel combination therapies, selecting optimal cancer indications, identifying patient biomarkers, and elucidating the mechanism of action of STAR-001 during the summit [1] - The presentation will emphasize AI-driven insights that address challenges in treating aggressive brain cancers like glioblastoma and atypical teratoid/rhabdoid tumors (ATRT) [1]

Company Overview - Lantern Pharma is leveraging its AI platform, RADR®, to transform cancer drug discovery and development, aiming to reduce costs and accelerate timelines[5, 6] - The company has raised approximately $100 million in total capital since 2019[5] - RADR® can predict and stratify real-world patients for clinical trials with 88% accuracy[6] - Lantern has 12 disclosed and collaborative lead drug programs[11] Drug Development Programs - LP-300, targeting Non-Small Cell Lung Cancer (NSCLC) in never smokers, represents a $4+ billion global annual market potential and is currently in Phase 2 clinical trials[23, 24] - Initial Phase 2 trial data for LP-300 showed an 86% clinical benefit rate in the safety lead-in cohort[38, 43] - LP-184, targeting advanced solid tumors with DDR deficiencies, has a $14+ billion annual US market potential and is in Phase 1 clinical trials[54, 55] - LP-284, targeting B-cell Non-Hodgkin's Lymphomas (NHL), represents a $4 billion annual global market potential and is also in Phase 1 clinical trials[88, 89] AI Platform and Collaborations - Lantern's RADR® platform incorporates over 100 billion data points from 130K+ patient records and advanced ML algorithms[13] - The company has strategic collaborations with academic, research institutions, and biopharma companies to accelerate timelines and gain unique real-world insights[19, 20, 21]